CSL’s vaccine wins FDA approval

Company News

by David Murdoch

CSL Limited (ASX:CSL) has announced Seqirus, formerly bioCSL has received FDA approval of their influenza vaccine for people five years of age and older in the U.S.

The Food and Drug Administration approved AFLURIA QUADRIVALENT, extending the company’s portfolio of influenza vaccine offerings.

The influenza vaccine was first approved in the U.S. in August 2016 for people aged 18 and older, helps protect against two influenza A strain viruses and two B strain viruses.

The company says its committed to providing health care professionals and their patients with the broadest range of vaccine options available.

CSL Limited (ASX:CSL) last traded .79 of a per cent lower at $131.25.


 

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?